Main content

    Pancreatic Cancer Clinical Research

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov



    Adjuvant Therapy
     |  Neoadjuvant Therapy  |  Non-Metastatic Pancreatic Cancer  |  Metastatic Pancreatic Cancer  |  Pancreatic Neuroendocrine Tumors


    Active Trials


    Adjuvant Therapy

    Title: A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
    Description: This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery.
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 years and older, with histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study RTOG 0848

    Back to top

    Neoadjuvant Therapy

    Title: A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
    Description: This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery.
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 to 75 y/o, with a histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study S1505

    Back to top

    Non-Metastatic Pancreatic Cancer

    Title: A Randomized Phase II Study of Perioperative mFolfironix Versus Gemcitabine/Nab-paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
    Description: This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 to 75 y/o, who have histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study SWOG 1505

    Back to top

    Metastatic Pancreatic Cancer

    Title: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
    Description: This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improvement (metastatic).
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or cytologically documented pancreatic adenocarcinoma. Patients with pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study S1513


    Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

    Description: The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). Participants will be randomized in a 2:1 ratio to PAG or AG treatment.
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have stage IV pancreatic ductal adenocarcinoma (PDA) with histological confirmation of PDA via archived or fresh core biopsy of either the primary tumor or 1 metastatic site
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study HALO-109-301

    Title: A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
    Description: This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with FOLFIRINOX or FOLFIRINOX-like regimen
    Investigator: Stephanie Jeske, MD
    Eligibility: Subjects 18 y/o and older, with recurrent, locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after primary therapy with FOLFIRINOX or FOLFIRINOX-like regimen or were intolerant of it
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study PB1201

    Title: S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
    Description: This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared with combination chemotherapy alone in treating patients with newly diagnosed pancreatic cancer that has spread to other places in the body
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 to 75 y/o, who have newly diagnosed, untreated metastatic histologically or cytologically documented pancreatic adenocarcinoma; patients must not have known history of brain metastases
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study SWOG 1313

    Back to top

    Pancreatic Neuroendocrine Tumors

    Title: Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
    Description: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older, who have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma of the gastrointestinal (GI) tract
    Status: Contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study EA2142

    • updated December 2016

    Back to top